HLNE vs NNI

HLNE exhibits exceptional fundamental health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.28. While the current price of $92.28 trades at a premium to its Graham Number ($49.52) and Intrinsic Value ($71.80), it remains significantly undervalued relative to its analyst target of $155.14 and sector average P/E. The stock is currently experiencing a severe technical correction, trading near its 52-week low, which creates a compelling entry point for a company with 31.7% ROE and consistent earnings beats. The divergence between deteriorating price action and strengthening financial health suggests a high-probability reversal.

NNI presents a conflicting profile: while the Graham Number ($165.02) suggests defensive value, the Piotroski F-Score of 3/9 indicates weak financial health and deteriorating fundamentals. The stock trades at a low P/E of 12.03 and a very attractive PEG of 0.46, yet it is significantly overpriced relative to its growth-based intrinsic value of $82.46. Negative year-over-year revenue and earnings growth, combined with a bearish technical trend and insider selling, offset the strong liquidity provided by a current ratio of 5.33.